CN-122012306-A - Lactobacillus plantarum and application thereof in promoting bone health and regulating intestinal flora

Abstract

The invention discloses lactobacillus plantarum and application thereof in promoting bone health and regulating intestinal flora. The lactobacillus plantarum is named as lactobacillus plantarum GXS77, the preservation number is CGMCC No.35899, and the strain is preserved in China general microbiological culture Collection center of No.3 of the Barbary 1 of North Star West Lu No. 1 of the Chaoyang district of Beijing in 2025. The yield of the lactobacillus plantarum GXS77 acetic acid and butyric acid obtained by screening is respectively improved by 18 percent and 16 percent relative to the yield of the acetic acid and the yield of the butyric acid of common lactobacillus plantarum, the peak calcium absorption capacity of Caco-2 cells can be improved by 12.3 percent, osteoblast differentiation is realized, bone health is promoted, and meanwhile, the lactobacillus plantarum GXS77 has good acid resistance, bile salt resistance and good cell adhesion effect. Therefore, the method can be used for developing fermented foods, health products and medicines with the effects of promoting bone health, regulating intestinal flora and the like.

Inventors

• LOU WENYONG
• TANG JINWEN
• LI XIN
• LIU ZHIQING
• XIAO LU

Assignees

• 华南理工大学

Dates

Publication Date

20260512

Application Date

20251231

Claims (10)

1. 1. The lactobacillus plantarum is characterized by being named as lactobacillus plantarum LactiplantibacillusplantarumGXS and having a preservation number of CGMCC No. 35899, and is preserved in China general microbiological culture Collection center of Seagaku 1 and 3 of the Yangyang area North Star of Beijing city in 2025.
2. 2. The lactobacillus plantarum according to claim 1, wherein the 16S rDNA gene sequence of the lactobacillus plantarum GXS77 is shown in SEQ ID No. 1.
3. 3. A strain of lactobacillus plantarum according to claim 1, characterized in that the lactobacillus plantarum GXS77 has a relatively high acetic acid and butyric acid yield, respectively 18% and 16% higher than the acetic acid and butyric acid yields of normal lactobacillus plantarum.
4. 4. The lactobacillus plantarum according to claim 1, wherein the lactobacillus plantarum GXS77 lactobacillus plantarum has better tolerance capability, higher intestinal adhesion and antibacterial activity, can inhibit the growth and reproduction of pathogenic bacteria, and is beneficial to maintaining the normal microbial flora balance of intestinal tracts.
5. 5. Intracellular enzymes involved in the synthesis of short chain fatty acids such as acetic acid and butyric acid in lactobacillus plantarum according to claim 1, wherein said intracellular enzymes comprise acetate kinase ack, phosphoacetyltransferase pta, phosphotransacetylbutyrate gene ptb, 4-aminobutyric acid aminotransferase puuE and glutamate decarboxylase gadA.
6. 6. The use of lactobacillus plantarum according to any of claims 1-4 for bone health promotion.
7. 7. The use according to claim 6, wherein lactobacillus plantarum promotes calcium absorption by secreting acetic acid and butyric acid, promotes bone cell differentiation by promoting calcium absorption, and promotes bone health by promoting osteoblast differentiation.
8. 8. Use of lactobacillus plantarum according to any of claims 1 to 4 for regulating intestinal flora.
9. 9. A fermented product, characterized by being produced by fermentation using the Lactobacillus plantarum according to any one of claims 1 to 4.
10. 10. Use of at least one of lactobacillus plantarum according to any of claims 1-4, intracellular enzyme according to claim 5, and fermented product according to claim 9 for the preparation of a product for increasing the content of intestinal acetic acid and/or butyric acid, promoting calcium absorption, promoting bone cell differentiation, improving bone crispness, promoting bone health, improving the structure of intestinal microbiota, inhibiting the growth and reproduction of pathogenic bacteria, maintaining the balance of intestinal normal microbiota.

Description

Lactobacillus plantarum and application thereof in promoting bone health and regulating intestinal flora Technical Field The invention belongs to the field of microbial engineering, and in particular relates to lactobacillus plantarum and application thereof in promoting bone health and regulating intestinal flora. Background Related studies have shown that bone mass is reduced as a precursor to osteoporosis with global prevalence of up to about 40%, and that osteoporosis itself has reached nearly 20%. Among them, although the fracture incidence in some European countries has been stabilized, the prevalence in North America is still increasing due to aging of population and insufficient treatment, and the number of fracture cases in Asia and Latin America is more sharply rising, and it is expected that hip fracture of more than half of the world in 2050 will occur in Asia. Moreover, female osteoporosis is at much higher risk than male, in the population over 50 years old, the definite prevalence of female diagnosis is about 4.5 times that of male, about one third of women in the world will experience osteoporosis fracture in life, while male is one fifth （Wang F., Wei W., Liu P.-J.,Effects of probiotic supplementation on bone health in postmenopausal women: a systematic review and meta-analysis,Frontiers in Endocrinology, 2024, 15:1487998). obviously, with the huge medical cost of billions of RMB per year, osteoporosis and its induced brittle fracture have become one of the most common metabolic bone diseases, belonging to the global public health problem to be treated urgently. Osteoporosis is a systemic bone disease characterized by reduced bone mass and destruction of bone tissue microstructure due to imbalance in bone metabolism, and is diagnosed when bone density (BMD) is determined using dual-energy X-ray absorption (DXA) and when the T value of bone density is less than or equal to-2.5. The dynamic balance of bone resorption (dominated by osteoclasts) and bone formation (dominated by osteoblasts) in the human body is broken, resulting in bone becoming porous and fragile when the rate of bone resorption exceeds the rate of bone formation. Osteoporosis often occurs without significant early symptoms, known as "silent killers," the most serious outcome of which is brittle fractures, usually in the vertebral body, hip, and wrist. The occurrence of fracture is often accompanied by symptoms such as severe pain, short height, kyphosis (humpback) and the like, and can induce complications such as long-term bedridden, pulmonary infection, thrombus and the like, and the mortality rate and disability rate of severe patients (especially after hip fracture) are extremely high, so that great pain is brought to patients, the life self-care ability is seriously affected, and the life expectancy is even obviously shortened. Because osteoporosis is a degenerative bone disease with a long course, the development of the osteoporosis is deeply influenced by various factors such as heredity, nutrition, living habit, hormone level and the like, and the osteoporosis has the characteristics of hidden disease and complex etiology, and the 'mainly prevention, prevention and control combination and comprehensive management' is a clinical consensus in the field of bone health. At present, clinical intervention mainly increases bone mass and reduces fracture risk by long-term use of drugs for resisting bone resorption or promoting bone formation, but long-term use of the existing drugs may be accompanied by potential side effects and potential safety hazards. Therefore, development of a novel functional intervention scheme with high safety, small side effects and suitability for long-term use for bone health, such as regulation of bone metabolism by probiotics, has become a current research hotspot. Disclosure of Invention The primary aim of the invention is to overcome the defects and shortcomings of the prior art and provide a lactobacillus plantarum. It is a second object of the present invention to provide a range of Lactobacillus plantarum intracellular enzymes. A third object of the present invention is to provide a fermented product containing Lactobacillus plantarum. The fourth object of the invention is to provide the application of the lactobacillus plantarum, the intracellular enzyme of the lactobacillus plantarum and the fermentation product containing the lactobacillus plantarum in products for promoting calcium absorption, osteoblast differentiation, improving bone crispness, promoting bone health, improving intestinal microbial flora structure, inhibiting growth and reproduction of pathogenic bacteria, maintaining normal microbial flora balance of intestinal tracts and increasing the content of acetic acid and/or butyric acid in the intestinal tracts. The aim of the invention is achieved by the following technical scheme: The invention provides a lactobacillus plantarum, which is named as lactobacillus plantarum GX